Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether lanreotide 30mg microparticles are
effective in the relief of clinical symptoms due to small bowel obstruction in inoperable
patients with peritoneal carcinomatosis.